Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Proteoglycan 3, pro-eosinophil major basic protein 2 (PRG3)
- Target
- PRG3
- Molecular classification
- Other (extracellular matrix glycoprotein/protein)
01
Overview
Proteoglycan 3, pro-eosinophil major basic protein 2 (PRG3) is an extracellular matrix protein primarily expressed in eosinophil granulocytes. It acts as a structural constituent conferring compression resistance in tissues and is involved in granulocyte activation. In vitro, PRG3 exhibits cytotoxic and cytostimulatory activities similar to those of PRG2/major basic protein, such as stimulating neutrophil superoxide production and interleukin-8 (IL-8) release. Its structure contains several cysteine disulfide linkages, and it is encoded by the PRG3 gene on chromosome 11. While it plays a role in immune cell function, there is limited evidence that PRG3 is currently a direct therapeutic target, nor are there known drugs or specific safety concerns associated with this molecule at this time[4][6].
- Other names
- PRG3Proteoglycan 3Proeosinophil major basic protein 2
02
Biological functions
Granulocyte activationExtracellular matrix structural constituentCytostimulatory activityStimulation of neutrophil superoxide productionInduction of IL-8 release
03
Disease associations
Other (direct disease associations not clearly established; related to immune and inflammatory response based on analogy with PRG2)
Beyond the preview
Go deeper on Proteoglycan 3, pro-eosinophil major basic protein 2 (PRG3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Proteoglycan 3, pro-eosinophil major basic protein 2 (PRG3).